EGFR and non-small cell lung carcinoma: A phase 2 study showed that osimertinib, 160 mg, could result in a promising intracranial ORR of 55.0% and a median PFS of 7.6 months in patients with EGFR T790M–positive NSCLC and brain metastases who progressed with prior EGFR TKI therapy,15 suggesting the potential of high-dose strategy.